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Immune escapeThe involvement of hepatitis B virus X protein (HBx) in anti-complement-dependent cytotoxicity
(CDC) activity during hepatocarcinogenesis is poorly understood. Here, we report that HBx is able
to up-regulate membrane-bound complement regulatory protein CD46 in hepatoma cells and
human immortalized liver cells through activating the promoter activity involving cAMP response
element-binding protein (CREB)/cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2)/signal transduc-
ers and activators of transcription 3 (STAT3) signaling pathway. In contrast, the down-regulation of
CD46 abolishes the resistance capability of hepatoma cells to CDC. Thus, we conclude that HBx con-
tributes to the protection of hepatoma and hepatic cells from CDC by up-regulation of CD46.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is a common and aggressive
cancer that is strongly associated with the chronic infection by
hepatitis B virus (HBV) [1]. HBV-associated carcinogenesis is now
considered a multifactorial process that largely depends on the
efﬁcacy of the host immune response to the virus [2]. HBV X pro-
tein (HBx), a protein encoded by HBV X gene, involved in viral
pathogenesis and carcinogenesis [3]. HBx is known to activate var-
ious signaling pathways, including NF-jB, which may subse-
quently alter antigen presentation and affect the immune
response [4]. Although many researchers suggest that chronicHBV infection results from multiple factors, including HBV-im-
mune suppression [2,4], the mechanism of HBV persistence and es-
cape from immune surveillance in the development of HBV-
associated HCC is not fully understood.
Complement is a vital part of the human immune system, pro-
viding a highly effective means for the destruction of invading
microorganisms and for immune complex elimination [5]. Cancer
cells frequently escape recognition and elimination by the immune
system. This may be in part due to expression of membrane-bound
complement-regulatory proteins (mCRPs) [6–8], including CD46
(membrane cofactor protein, MCP), CD55 (decay accelerating fac-
tor, DAF) and CD59 (protectin) [9]. The increased expression of
mCRPs has been described in several different malignancies,
including those of the liver and breast [6,9–14]. We have reported
that HBx is able to activate CD59, then protects hepatoma and he-
patic cells from complement attack [14]. CD46 is a cleavage cofac-
tor in the factor I-mediated cleavage of C3b and C4b, thereby
preventing cells from initiating CDC [11–13]. Importantly, CD46
also plays crucial roles in the process of inhibiting complement
activation in HCC [12].
In the present study, we hypothesized that the over-expression
of CD46 in hepatoma cells was involved in the development of
HBV-associated HCC as well. We focused on the investigation of
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opment of HCC. Our data suggest that HBx contributes to the resis-
tance of CDC in the cells through up-regulating CD46. This ﬁnding
provides new insights into the mechanism of HBx-mediated resis-
tance of CDC involving the complement system in the development
of HCC (Tables S1 and S2).
2. Materials and methods
The details of methods are described in Supplementary
methods.
2.1. Cell lines and cell culture
Hepatoma cell lines HepG2, HepG2-P, HepG2-X and HepG2.2.15
cell lines were maintained in DMEM (Gibco, CA, USA). H7402,
H7402-P and H7402-X cell lines [15–18], human immortalized liver
cell lines L-O2, L-O2-pcDNA3, and L-O2-X cell lines [18] weremain-
tained in RPMI Medium 1640 (Gibco, CA, USA) supplemented with
heat inactivated 10% fetal calf serum (FCS), 100 U/ml penicillin,
and 100 mg/ml streptomycin in 5% CO2 at 37 C.
2.2. Patient samples
The 11 clinical HCC tissues and the corresponding nearby non-
cancerous livers used in this study were obtained from patients
who underwent radical resection at Tianjin First Center Hospital
(Tianjin, China). Specimens were immediately frozen and stored at
80 C.
2.3. Statistical analysis
Data were analyzed using SPSS software v.13.0 (Chicago, IL,
USA). Each experiment was repeated at least 3 times. Statistical
signiﬁcance was assessed by comparing the mean values (±SD)
using a Student’s t test.
3. Results
3.1. HBx is able to up-regulate CD46
It has been reported that CRPs are responsible for evading im-
mune surveillance and CDC, which are up-regulated in hepatoma
cells [12–14]. Previously, we reported that HBx was able to up-reg-
ulate CD59 to protect hepatoma and hepatic cells from complement
attack [14]. Accordingly,we are interested inwhetherHBx is capable
of protecting hepatoma and hepatic cells fromCDCby up-regulating
CD46. Then, we examined the expression levels of CD46 by IHC
staining assay in clinical HCC tissues. Our data showed that the po-
sitive rate of CD46was 74.4% (67/90) in clinicalHCC tissues (Fig. 1A),
suggesting that the over-expression of CD46may play an important
role in thedevelopmentofHCC.Meanwhile,we found thatCD46was
up-regulated inHBx-positive HCC tissues relative to their surround-
ing non-tumor tissues (P < 0.05, Student’s t test, Fig. 1B). We ob-
served that the expression levels of the HBx gene were higher in
all 11 clinical HCC tissues than those in their surrounding non-
tumorous tissues (P < 0.001, Wilcoxon signed-rank test, Fig. S1A).
Interestingly, the HBx expression levels were positively correlated
with those of CD46 in HCC tissues (Fig. S1B). Thus, we supposed that
HBxmight up-regulate CD46 in hepatoma cells. Next, we tested the
effect of HBx on the regulation of CD46 in hepatoma cells and liver
cells.We observed that the promoter activity of CD46was increased
in the systems of stable transfection and transient transfectionwith
pCMV-Xplasmids in a dose-dependentmanner, suggesting thatHBx
is able to activate the CD46 promoter (Fig. 1C). The expression levelsof CD46 were increased in HBx-expressing hepatoma and hepatic
cells. The down-regulation of HBx by RNAi abolished the up-regula-
tion of CD46 (P < 0.05, Student’s t test, Fig. 1D and E). In addition,
Western blot analysis showed that HBx was able to up-regulate
the expression of CD46 by transient transfection with pCMV-X
(encodingHBx) plasmids in a dose-dependentmanner (Fig. S2). Fur-
thermore, the expression levels of CD46 were higher in HepG2.2.15
cells which constitutively replicate HBV relative to HepG2 cells
(Fig. S3). Thus, we conclude that HBx up-regulates CD46 in hepa-
toma cells and liver cells.
3.2. HBx up-regulates CD46 through STAT3
To identify the mechanism bywhich HBx up-regulates CD46, we
performed the analysis of transcription factor binding sites in the
CD46promoter regionbyTFSEARCHanalysis (Fig. S4). It has been re-
ported that CD46 promoter activities are induced by STAT3 through
binding to the region of CD46 promoter [19]. Thereby, we are inter-
ested in whether HBx up-regulates CD46 through STAT3. Western
blot analysis showed that the phosphorylation levels of STAT3 (p-
STAT3) were signiﬁcantly increased by HBx (Fig. 2A). Then, we
examined whether the activated STAT3 could affect the expression
of CD46 mediated by HBx. Western blotting analysis showed that
the treatment of STAT3 siRNA-1 and STAT3 siRNA-2 could result in
the down-regulation of CD46 in HBx-expressing cells (Fig. 2B,
Fig. S5A). Moreover, luciferase reporter gene assays revealed that
HBx failed to activate the CD46 promoter when the STAT3-binding
site was mutated in the CD46 promoter (Fig. 2C, upper) or when
STAT3 was silenced by STAT3 siRNA-1 in a dose-dependent manner
(Fig. 2C, lower). Meanwhile, the treatmentwith 80 nMSTAT3 siRNA-
1 resulted in the reduced cytotoxic effect in HBx-expressing cells
(Fig. 2D). These ﬁndings indicate that HBx is responsible for the
up-regulation of CD46 through STAT3. However, the mechanism
underlying STAT3 activation mediated by HBx remains unclear.
3.3. HBx activates STAT3 through PGE2 produced by COX-2
Liu et al. reported that PGE2 induced a signiﬁcant elevation of p-
STAT3 levels [20]. We validated the ﬁnding and showed that the
treatment with PGE2 was able to increase the levels of p-STAT3
in a dose-dependent manner (Fig. S5B). In our previous studies,
we demonstrated that HBx was able to increase the levels of
PGE2 which was produced by COX-2 [21,22]. Here, we examined
the effect of COX-2 on the levels of p-STAT3 by treatment with
indomethacin (indo, an inhibitor of COX-2) or COX-2 siRNA in
HBx-expressing cells. We found that the treatment with indo or
COX-2 siRNA-1 signiﬁcantly attenuated the level of p-STAT3
(Fig. 2E and 2F). Thus, our results suggest that HBx activates STAT3
through PGE2 produced by COX-2.3.4. HBx activates COX-2 promoter via cAMP response element-
binding protein (CREB)
Our previous studies demonstrated that HBx could up-regulate
COX-2 in H7402-X cells [21]. In this study, we validated that COX-2
was up-regulated in HepG2-X cells (Fig. S5C). However, the mech-
anism by which HBx up-regulates COX-2 remains unclear. We
found that HBx was able to activate COX-2 promoter by luciferase
reporter gene assays (Fig. 3A left). It has been reported that the pro-
moter region of COX-2 contains CREB element [23]. Interestingly,
we revealed that HBx failed to activate the COX-2 promoter when
the CREB-binding site in the COX-2 promoter was mutated or
when CREB was inhibited by CREB siRNA by luciferase reporter
gene assays (Fig. 3A right). This ﬁnding suggests that HBx activates
COX-2 promoter through CREB.
Fig. 1. HBx up-regulates the expression of CD46. (A) The expression of CD46 was detected by IHC in human HCC tissues using HCC tissue microarray. (B) The mRNA levels of
CD46 were examined by real time PCR in human HCC tissues and their surrounding non-tumor tissues. (C) The promoter activities of CD46 were examined by luciferase
reporter gene assay. The value represents the mean ± SD of at least three independent transfection experiments. (D, E) The expression of CD46 was detected by real-time PCR
and Western blot analysis in hepatoma cells, respectively.
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To examine whether COX-2 is able to up-regulate CD46, we
examined the effect of indo or COX-2 siRNA (COX-2 siRNA-1 and
COX-2 siRNA-2) on CD46 in HBx-expressing cells. The data showed
that the treatment signiﬁcantly attenuated the expression of CD46
in the cells (Fig. 3B, Fig. S5D). Moreover, the promoter activity of
CD46 was decreased in the cells by treatment with COX-2 siRNA-1 or indo (Fig. 3C). Thus, we conclude that COX-2 contributes to
the up-regulation of CD46 in the cells.
3.6. The released PGE2 is able to up-regulate CD46
We are interested in whether the released PGE2 in the condi-
tioned media is involved in the up-regulation of CD46. Then, we
examined the effect of the conditioned media from HBx-expressing
Fig. 2. HBx up-regulates CD46 through STAT3. (A) The levels of p-STAT3 were examined in HepG2-X cells by Western blot analysis. (B) The levels of CD46 were examined in
HepG2-X and L-O2-X cells treated with STAT3 siRNA-1 by Western blot analysis. (C) The promoter activities of CD46 were examined by luciferase reporter gene assays when
the STAT3-binding site in the promoter region of CD46 was deleted, or when the cells were treated with STAT3 siRNA-1 (P < 0.01, Student’s t test). (D) The effect of knockdown
of STAT3 by siRNA on CDC was examined by Trypan blue absorbance assay (% lysis = lysis cells/total cells). (E) The expression levels of CD46 were examined in HBx-expressing
cells by Western blot analysis when the cells were treated with indo (an inhibitor of COX-2). (F) The expression levels of CD46 were examined in HBx-expressing cells by
Western blot analysis when the cells were treated with COX-2 siRNA-1.
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rule out the possibility that the proteins in the conditioned media
may affect the expression of CD46, we boiled the media. Western
blot analysis showed that both boiled and non-boiled HBx-
expressing cells-CM strongly induced the expression of CD46 in
hepatoma and hepatic cells in a dose-dependent manner
(Fig. 3D). In control, the media from HepG2 (HepG2-CM) did not al-
ter the levels of CD46 in HepG2 cells (Fig. S5E). Meanwhile, we
found that the amounts of PGE2 were higher in the conditionedmedia of HepG2-X cells than those in the conditioned media of
HepG2 cells by ELISA. Interestingly, the increased PGE2 could be
abolished by pre-treatment with indo (P < 0.05, Student’s t test,
Fig. S5F). The CD46 promoter activities were increased in HepG2
and LO2 cells by the addition of PGE2 in a dose-dependent manner
(Fig. 3E). Functionally, HBx-expressing cells became more sensitive
to CDC when the cells were treated with COX-2 siRNA-1 (Fig. 3F).
Thus, we conclude that the released PGE2 produced by COX-2 is
responsible for up-regulation of CD46 in response to CDC.
Fig. 3. HBx up-regulates CD46 via COX-2. (A) Left panel: The promoter activities of COX-2 were examined by luciferase reporter gene assays in HBx-expressing cells (P < 0.01,
Student’s t test). Right panel: The promoter activities of COX-2 were examined by luciferase reporter gene assays when the CREB-binding site in the promoter region of COX-2
was mutated, or when the cells were treated with CREB siRNA (P < 0.01, Student’s t test). (B) The expression levels of CD46 were examined in HepG2-X cells treated with indo
or COX-2 siRNA-1 by Western blot analysis. (C) The promoter activities of CD46 were examined by luciferase reporter gene assays in the cells treated with COX-2 siRNA-1 or
indo (P < 0.01, Student’s t test). (D) The expression levels of CD46 were examined in HepG2 or L-O2 cells treated with conditioned media from HBx-expressing cells (HepG2-X
CM or L-O2-X CM) or boiled conditioned media from HBx-positive cells (HepG2-X BCM or L-O2-X BCM) by Western blot analysis. (E) The promoter activities of CD46 were
examined by luciferase reporter gene assays in the cells treated with PGE2. (F) The effect of knockdown of COX-2 by siRNA on CDC was examined by Trypan blue absorbance
assay (% lysis = lysis cells/total cells).
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Next, we examined the effect of CD46 on the HBx-expressing
cells in protection of CDC by siRNA targeting CD46 mRNA. Western
blot analysis conﬁrmed that protein levels of CD46 were signiﬁ-
cantly reduced in the treated cells (Fig. 4A, Fig. S6). CDC analysis
showed that the down-regulation of CD46 resulted in the increasedsensitivity of HBx-expressing cells to CDC (Fig. 4B, Fig. S7). In our
previous studies, CDC analysis showed that the CD59 siRNA in-
creased the sensitivity of HBx-expressing cells to CDC [14]. In this
study, we compared the effect of CD59 and CD46 on CDC by treat-
ment with siRNA targeting CD59 or/and CD46. The data showed
that the down-regulation of both CD46 and CD59 by siRNA re-
sulted in more sensitivity of HBx-expressing cells to CDC than
the down-regulation of CD46 or CD59 alone (Fig. 4B). To further
Fig. 4. Down-regulation of CD46 increases the sensitivity of hepatoma cells to CDC. (A) The expression levels of CD46 were detected by Western blot analysis when the cells
were treated with 100 nM CD46 siRNA-1. (B) The effect of knockdown of CD46 (and/or CD59) by CD46 siRNA-2 (and/or CD59 siRNA-2) on CDC was examined by Trypan blue
absorbance assay (% lysis = lysis cells/total cells). (C) The deposition of C3b in hepatoma and hepatic cells was detected by ELISA in the cells treated with 100 nM CD46 siRNA-
1 (P < 0.05, vs. siRNA controls, Student’s t test). (D) The average tumor volume from a xenograft model injected with HepG2-X cells pretreated with 100 nM CD46 siRNA-1. (E)
Tumors were from a xenograft model, in which the expression levels of CD46 were examined by Western blot analysis.
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tack, we examined the effect of CD46 siRNA-1 (or HBx RNAi) on the
deposition of C3b by ELISA. The data showed that the deposition of
C3b on the cell surface was decreased in HepG2-X cells relative to
HepG2 cells. However, the treatment with 100 nM CD46 siRNA-1
(or HBx RNAi) could increase the deposition of C3b on the cell sur-
face in HepG2 or HepG2-X cells relative to control cells (P < 0.05,
Student’s t test, Fig. 4C), suggesting that CD46 contributes to the
depression of the complement cascade. It has been reported that
CD59 is involved in the growth of tumor cells [24]. Accordingly,
we observed that the tumor growth of HepG2-X cells pre-treated
with CD46 siRNA-1 was signiﬁcantly inhibited in nude mice with
health complement system (P < 0.05, vs. control, Student’s t test,
Fig. 4D, E left). Meanwhile, Western blot analysis conﬁrmed that
the expression levels of CD46 were down-regulated by CD46 siR-
NA-1 in the tumor tissues from the mice (Fig. 4E, right). Thus, we
conclude that CD46 decreases the sensitivity of HBx-expressing
hepatoma cells to CDC.
4. Discussion
Growing evidence shows that HBx contributes to the develop-
ment of HCC. In particular, HBx plays an important role in modu-
lating the immune response and tumor progression [4,25,26]. It
has been reported that the expression levels of mCRPs are
up-regulated in tumor tissues or tumor cells [6,9–13], not onlyprotecting tumor cells from CDC [9,13], but also promoting tumor
cell growth in vivo [24]. However, the mechanisms involved in the
HBx-mediated anti-CDC of hepatoma and hepatic cells have not
been fully elucidated so far. Previously, we reported that HBx
was able to up-regulate CD59 to protect hepatoma and hepatic
cells from complement attack [14]. In this study, we are interested
in whether HBx is capable of protecting hepatoma and hepatic cells
from CDC by up-regulating CD46 as well.
It has been reported that the expression levels of the CD46 are
signiﬁcantly higher in HCC tissues than those in the tissues of nor-
mal liver, chronic hepatitis and liver cirrhosis [12]. CD46 plays a
major role in inhibiting complement activation in tumor [27]. In
our study, we observed that the expression of CD46 was up-regu-
lated in HBx-expressing cells and HCC tissues relative to their sur-
rounding non-tumorous tissues. Moreover, we found that the CD46
was highly expressed (74.4%, 67/90) in clinical HCC tissues, sug-
gesting that CD46 may play a role in the suppression of comple-
ment activation in HCC. Given this information, we hypothesized
that HBx might exert an immunosuppressive function, partially
by up-regulating CD46 in HBx-induced hepatocarcinogenesis. In
addition, our data showed that HBx has no effect on the expression
of CD55 (data not shown). Therefore, we focused on the investiga-
tion of the mechanism by which HBx up-regulates CD46 in com-
plement attack escape. Buettner et al. reported that CD46
promoter activity could be induced by activation of STAT3 [19],
whereas the STAT3 signaling pathway can be activated by HBx
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was caused by STAT3, we examined the expression levels of
CD46 and its promoter activity by using either STAT3 siRNA or
STAT3 site-directed mutagenesis on CD46 promoter. We observed
that the CD46 promoter activity was decreased and the protein lev-
els were reduced in the HBx-expressing cells. STAT3 siRNA also in-
creased the sensitivity of HBx-expressing cells to CDC, suggesting
that HBx accelerates anti-CDC through activation of the STAT3
pathway. However, the mechanism by which HBx activates STAT3
remains unclear.
Wehave reported thatHBx is responsible for the up-regulation of
COX-2, which catalyzes the conversion of arachidonic acid to PGE2
[21,22]. Interestingly, it has been reported that PGE2 is able to acti-
vate STAT3 [23]. Thus, we speculated that PGE2 may activate CD46
through STAT3. We observed that the expression levels of STAT3
were decreased by the treatment with COX-2 inhibitors in HBx-
expressing cells and found that the additionof PGE2was able to acti-
vate STAT3 in the cells, suggesting that HBx up-regulates STAT3 via
COX-2 involving PGE2. Furthermore, our data showed that COX-2
and PGE2were responsible for the up-regulation of CD46. However,
Astier et al. reported that PGE2 decreased the CD46 expression in
activated T cells through inhibiting STAT3 phosphorylation [29].
The opposite results may be related to the difference cells, one is
in cancer cells with the capability of immune escape and another
in activated T cells. Although HBx is responsible for the up-regula-
tion of COX-2, the mechanism of up-regulation of COX-2 by HBx re-
mains unclear. Interestingly, it has been reported that the promoter
region of COX-2 contains the CREBelement [23]. Here,we found that
HBx was able to activate COX-2 promoter via transcription factor
CREB. Thereby, our data suggest that HBx is able to up-regulate
CD46 through STAT3 signaling. Moreover, we revealed that HBx in-
creased the production of PGE2 via up-regulating COX-2 and then
activated STAT3, which resulted in the up-regulation of CD46. CDC
and tumor formation assays further revealed that HBx contributed
to the protection of hepatoma and hepatic cells from complement
system attack, at least partly through the up-regulation of CD46
in vitro and in vivo. Therefore, the block of CD46 will be beneﬁt to
the demission of HBx-induced protection of hepatoma cells from
complement system attack in tumor therapy. More important,
HBx may serve as an important therapeutic target for HCC.
In summary, we report a novel ﬁnding of immune escape
involving CD46 in the development of HCC. Our data show that
HBx contributes to the escape of hepatoma cells and hepatic cells
from complement attack by up-regulating the expression of
CD46. CD46 may serve as a potential therapeutic target in HBV-
associated hepatoma patients.
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